Analysts at Deutsche Bank Reiterate their “Sell” rating for PageGroup Plc (LON:PAGE) with GBX 380.00 Target Price; Imprimis Pharmaceuticals (IMMY) Has 2.25 Sentiment

Imprimis Pharmaceuticals, Inc. engages in the development, production, and sale of medications to physicians and patients in the United States. The company has market cap of $36.98 million. The Company’s ophthalmology program consists of Dropless Therapy injectable and LessDrops topical formulations. It currently has negative earnings. The firm also offers a conscious sedation medication, the IV Free MKO Melt, an alternative to intravenous sedation.

PageGroup Plc (LON:PAGE) had its stock rating noted as “Sell” by analysts at Deutsche Bank. Deutsche Bank currently has a GBX 380.00 price target on the 1.62B GBP market cap company or -27.48% downside potential. This was released in a research note on Tuesday morning.

The stock decreased 3.26% or $0.06 during the last trading session, reaching $1.78. About 30,161 shares traded. Imprimis Pharmaceuticals, Inc. (IMMY) has declined 2.70% since March 27, 2017 and is downtrending. It has underperformed by 19.40% the S&P500.

Marathon Asset Management Lp holds 0.14% of its portfolio in Imprimis Pharmaceuticals, Inc. for 792,434 shares. Berson & Corrado Investment Advisors Llc owns 123,119 shares or 0.11% of their US portfolio. Moreover, Bard Associates Inc has 0.05% invested in the company for 60,700 shares. The California-based Granite Investment Partners Llc has invested 0.01% in the stock. Ardsley Advisory Partners, a Connecticut-based fund reported 20,000 shares.

The stock increased 1.75% or GBX 9 during the last trading session, reaching GBX 524. About 183,580 shares traded. PageGroup plc (LON:PAGE) has 0.00% since March 27, 2017 and is . It has underperformed by 16.70% the S&P500.

PageGroup plc, together with its subsidiaries, provides recruitment consultancy and support services in the United States and internationally. The company has market cap of 1.62 billion GBP. It offers recruitment services for executive, second/third job, technical and administrative support, professional clerical, and junior management levels on a permanent, temporary, contract, and interim basis. It has a 19.85 P/E ratio. The firm provides its services under the Page Executive, Michael Page, Page Personnel, Page Assessment, Page Consulting, Page Outsourcing, and Page Talent brands.

Among 15 analysts covering Pagegroup Plc (LON:PAGE), 5 have Buy rating, 4 Sell and 6 Hold. Therefore 33% are positive. Pagegroup Plc has GBX 640 highest and GBX 265 lowest target. GBX 489.60’s average target is -6.56% below currents GBX 524 stock price. Pagegroup Plc had 72 analyst reports since June 27, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Tuesday, July 11 by Liberum Capital. As per Tuesday, October 11, the company rating was maintained by Jefferies. The firm has “Underweight” rating by JP Morgan given on Monday, March 12. Kepler Cheuvreux upgraded the shares of PAGE in report on Tuesday, April 18 to “Buy” rating. Numis Securities maintained PageGroup plc (LON:PAGE) rating on Wednesday, October 12. Numis Securities has “Hold” rating and GBX 350 target. The rating was maintained by HSBC on Thursday, March 9 with “Buy”. As per Wednesday, October 12, the company rating was upgraded by Kepler Cheuvreux. Jefferies maintained the stock with “Hold” rating in Tuesday, April 11 report. The stock of PageGroup plc (LON:PAGE) has “Underweight” rating given on Wednesday, July 13 by JP Morgan. The firm has “Sell” rating given on Friday, August 12 by Deutsche Bank.